JPRN-UMIN000030343已完成未知
Comparison of canagliflozin vs. tenegliptin against basic metabolic risks in patients with type 2 diabetes mellitus - CANTABILE study
ational Cerebral and Cardiovascular Center0 个研究点目标入组 200 人开始时间: 2018年1月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Type 1 diabetes mellitus 2. BMI of 22 kg/m2 or less 3. Hypersensitivity to contents of TENELIA or CANAGLU 4. Require insulin therapy (Severe ketosis, diabetic coma or precoma, severe infection, perioperative, severe trauma etc.) 5. Congestive heart failure of NYHA III or IV 6. Pregnancy, possible pregnancy, or lactating 7. Malignancy or suspected malignancy 8. Taking unallowed medications or undertaking unallowed therapy defined in the study protocol during the preceding 8 weeks 9. Changes in dosage of concomittantly administered drugs or therapy contents during the preceding 8 weeks 10. Other subjects deemed unsuitable by the doctor in charge of the research
研究者
相似试验
已完成
4 期
A clinical trial to compare the effects of Canagliflozin and Sitagliptin in Patients with Type 2 Diabetes mellitus on a background metformin therapy.CTRI/2019/02/017435SRM College of Pharmacy40
已完成
不适用
Comparison of efficacy of Teneligliptin and Sitagliptin for glucose fluctuation in Type 2 diabetesType 2 diabetesJPRN-UMIN000022885niversity of Occupational and Environmental Health, Japan, First Department of Internal Medicine, School of Medicine20
已完成
不适用
Efficacy of canagliflozin versus liraglutide, alternative to bolus insulin in patients with basal-bolus regimen.Type 2 diabetes mellitusJPRN-UMIN000019382Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University School of Medicine40
招募中
不适用
The efficacy and safety of Canagliflozin for the treatment of NAFLD/NASH patients with type2 DMAFLD/NASHJPRN-UMIN000036560ippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology30
招募中
不适用
A study to understand the combined effect of sitagliptin and teneligliptin with metformin in comparison to metformin alone treatment on blood glucose cotrol in patients with type 2 diabetes mellitus.CTRI/2018/03/012413Department of Pharmacology and Therapeutics